In conclusion, we did not observe any clinically remarkable effects of 12-week treatment with azilsartan and telmisartan on the variables of insulin resistance and the disease state of diabetes mellitus, including HOMA-R, fasting blood glucose, fasting insulin, HbA1c (NGSP), HOMA-β, and 1, 5-AG in hypertensive patients with type 2 diabetes mellitus enrolled in this study. This evidence concerns the gene INS and diabetes mellitus.